SCHEMBL412732

SCHEMBL412732

C#CC(C)Oc1cccc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1B P28222 5/20 0.44
SLC6A4 P31645 9/20 0.43
SLC6A2 P23975 5/20 0.43
NR2E1 Q9Y466 5/20 0.43
CYP1A2 P05177 4/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.42
CYP2D6 P10635 4/20 0.40
ALDH1A1 P00352 3/20 0.40
ADRB2 P07550 3/20 0.40
ADRB1 P08588 3/20 0.40
HTR2B P41595 3/20 0.40
SIGMAR1 Q99720 3/20 0.40
ADRB3 P13945 2/20 0.40
HTR2A P28223 2/20 0.40
HTR2C P28335 2/20 0.40
SCN1A P35498 2/20 0.40
HTR6 P50406 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7345604 0.82 HTR1B (0.44) HTR1BSLC6A4SLC6A2NR2E1CYP1A2
SCHEMBL10588548 0.82 HTR1B (0.44) HTR1BSLC6A4SLC6A2NR2E1CYP1A2
SCHEMBL10629672 0.81 HTR1B (0.43) HTR1BSLC6A4SLC6A2NR2E1CYP1A2
SCHEMBL4982131 0.79 CYP1A2 (0.56) HTR1BSLC6A4SLC6A2NR2E1CYP1A2
SCHEMBL6831487 0.79 HTR1B (0.50) HTR1BSLC6A4SLC6A2NR2E1CYP1A2
SCHEMBL23067897 0.76 HTR1B (0.47) HTR1BSLC6A4SLC6A2NR2E1CYP1A2
SCHEMBL8344333 0.76 MCHR1 (0.51) HTR1BSLC6A4SLC6A2NR2E1CYP1A2
SCHEMBL8743533 0.76 ADRA2A (0.44) SLC6A4SLC6A2MEN1KMT2AALDH1A1
SCHEMBL1356983 0.76 HTR1B (0.47) HTR1BSLC6A4SLC6A2NR2E1CYP1A2
SCHEMBL1356985 0.76 CYP1A2 (0.54) HTR1BSLC6A4SLC6A2NR2E1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10125116-B2 Compounds and methods for treating mammalian gastrointestinal microbial infections BRANDEIS UNIVERSITY (US) 2018-11-13 US disclosed
US-20150099781-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-09 US disclosed
US-8969342-B2 Compounds and methods for treating mammalian gastrointestinal microbial infections BRANDEIS UNIVERSITY (US) 2015-03-03 US disclosed
US-20120101096-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections University of Georgia Foundation, Inc. (US) 2012-04-26 US disclosed
EP-2408753-A2 COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS Brandeis University (US) 2012-01-25 EP disclosed
WO-2010108187-A2 COMPOUNDS AND METHODS FOR TREATING MAMMALIAN GASTROINTESTINAL MICROBIAL INFECTIONS BRANDEIS UNIVERSITY (US) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101096-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections IMPDH1, IMPDH2, IMPA1 HTR1B 3204/4885SLC6A4 907/4885SLC6A2 719/4885
US-10125116-B2 Compounds and methods for treating mammalian gastrointestinal microbial infections IMPDH1, IMPDH2, IMPA1 HTR1B 3204/4885SLC6A4 907/4885SLC6A2 719/4885
US-20150099781-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections IMPDH1, IMPDH2, IMPA1 HTR1B 3204/4885SLC6A4 907/4885SLC6A2 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.